[go: up one dir, main page]

MX2022011437A - Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. - Google Patents

Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.

Info

Publication number
MX2022011437A
MX2022011437A MX2022011437A MX2022011437A MX2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A
Authority
MX
Mexico
Prior art keywords
degraders
stat
compositions
methods
same
Prior art date
Application number
MX2022011437A
Other languages
English (en)
Inventor
Bin Yang
Nan Ji
Xiaozhang Zheng
Xiao Zhu
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2022011437A publication Critical patent/MX2022011437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones de los mismos, y métodos para usar los mismos.
MX2022011437A 2020-03-17 2021-03-17 Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. MX2022011437A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990555P 2020-03-17 2020-03-17
US202063088945P 2020-10-07 2020-10-07
US202063123335P 2020-12-09 2020-12-09
US202163159102P 2021-03-10 2021-03-10
PCT/US2021/022794 WO2021188696A1 (en) 2020-03-17 2021-03-17 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011437A true MX2022011437A (es) 2022-10-03

Family

ID=77771311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011437A MX2022011437A (es) 2020-03-17 2021-03-17 Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.

Country Status (9)

Country Link
US (1) US20240016942A1 (es)
EP (1) EP4121055A4 (es)
JP (1) JP2023518422A (es)
CN (1) CN115776891A (es)
AU (1) AU2021238333A1 (es)
CA (1) CA3170503A1 (es)
IL (1) IL296334A (es)
MX (1) MX2022011437A (es)
WO (1) WO2021188696A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012216A (es) 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
CN115677831A (zh) * 2021-07-22 2023-02-03 杭州和正医药有限公司 拟肽类stat降解药物、组合物及应用
EP4444290A4 (en) * 2021-12-11 2025-11-26 Kymera Therapeutics Inc STAT3 DEGRADING AGENTS AND THEIR USES
WO2023192960A1 (en) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. Stat modulators and uses thereof
EP4565567A1 (en) * 2022-08-05 2025-06-11 Kymera Therapeutics, Inc. Deuterated stat3 degraders and uses thereof
WO2024173291A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
WO2024173298A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
WO2024233639A2 (en) * 2023-05-09 2024-11-14 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2024238603A2 (en) * 2023-05-15 2024-11-21 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2024263673A1 (en) * 2023-06-20 2024-12-26 Regents Of The University Of Michigan Compounds and compositions as vhl ligands and stat3 degraders uses thereof
CN117024254B (zh) * 2023-08-10 2025-09-09 浙江大学衢州研究院 一种多氟苯酚的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3076613A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2020248002A1 (en) * 2019-03-26 2021-10-21 The Regents Of The University Of Michigan Small molecule degraders of STAT3
EP3947403A1 (en) * 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
MX2021012216A (es) * 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.

Also Published As

Publication number Publication date
CA3170503A1 (en) 2021-09-23
JP2023518422A (ja) 2023-05-01
US20240016942A1 (en) 2024-01-18
CN115776891A (zh) 2023-03-10
WO2021188696A1 (en) 2021-09-23
AU2021238333A1 (en) 2022-09-29
EP4121055A1 (en) 2023-01-25
IL296334A (en) 2022-11-01
EP4121055A4 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
PH12023500015A1 (en) Irak degraders and uses thereof
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12022551524A1 (en) Irak degraders and uses thereof
WO2021127283A3 (en) Irak degraders and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
PH12021500026A1 (en) Irak degraders and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12023500023A1 (en) Cdk2 degraders and uses thereof
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
WO2024039901A3 (en) Cdk2 degraders and uses thereof
WO2023049790A3 (en) Mdm2 degraders and uses thereof
ZA202309446B (en) Rapamycin analogs and uses thereof
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2024005138A (es) Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
PH12021553018A1 (en) New egfr inhibitors
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof